Gepato-gastroenterologik tadqiqotlar jurnali 2025 №4

Тема статьи

BOLALARDA HELICOBACTER PYLORI INFEKTSIYASINING MOLEKULYAR DIAGNOSTIKASI VA IMMUNOGENETIK JAVOB: TIZIMLI ADABIYOTLAR TAHLILI (5-8)

Авторы

Ахmatov Ablokul

Учреждение

Samarqand davlat tibbiyot universiteti

Аннотация

Ushbu maqolada bolalarda Helicobacter pylori infeksiyasini aniqlashda zamonaviy molekulyar diagnostika yondashuvlarining ahamiyati tizimli ravishda tahlil qilindi. Bolalar populyatsiyasida H. pylori ning yuqori uchrash chastotasi, uning virulentlik omillari, perzistensiya mexanizmlari va gastroduodenal hamda sistemali kasalliklar rivojlanishidagi roli yoritildi. Invaziv va noinvaziv diagnostika usullarining sezgirlik va spetsifiklik ko‘rsatkichlari solishtirilib, PZR asosidagi molekulyar testlarning ustunliklari ko‘rsatib berildi. Antibiotiklarga chidamlilikning oshib borishi fonida davolash strategiyalari, genotipik testlar, probiotik qo‘shimchalar va Bismut asosidagi terapiyalar qo‘llanilishining samaradorligi tahlil qilindi. Hozirgi dalillar H. pylori infeksiyasida individual yondashuvga asoslangan diagnostika va davolash strategiyalarini kengaytirish zarurligini asoslaydi.

Ключевые слова

Kalit so‘zlar: Helicobacter pylori; bolalar; molekulyar diagnostika; polimeraza zanjirli reaksiya (PZR); vismutli preparatlar; gastrit va peptik yara; epidemiologiya; erta aniqlash strategiyalari.

Литературы

Список литературы/ Iqtiboslar / References 1. Malfertheiner, P., Megraud, F., O'Morain, C. A., et al. (2017). Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report. Gut, 66(1), 6-30. 2. Chey, W. D., Leontiadis, G. I., Howden, C. W., & Moss, S. F. (2017). ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. American Journal of Gastroenterology, 112(2), 212–239. 3. Graham, D. Y., Fischbach, L. A. (2010). Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut, 59(8), 1143-1153. 4. Megraud, F., Lehours, P. (2007). Helicobacter pylori detection and antimicrobial susceptibility testing. Clinical Microbiology Reviews, 20(2), 280–322. 5. Fallone, C. A., Chiba, N., van Zanten, S. V., et al. (2016). The Toronto Consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology, 151(1), 51-69.e14. 6. Li, Y., Chen, L., Zhang, Z., et al. (2022). Genotypic resistance testing for Helicobacter pylori infection: A meta-analysis and systematic review. Helicobacter, 27(2), e12879. 7. Zhao, Y., Ren, F., Peng, J., et al. (2019). Probiotics as adjunct therapy for Helicobacter pylori eradication: a systematic review and meta-analysis. Helicobacter, 24(5), e12676. 8. Smith, S. L., Jones, M., et al. (2023). Advances in Helicobacter pylori vaccine development: a systematic review. Vaccine, 41(7), 1300-1310. 9. Backert, S., Clyne, M. (2011). Pathogenesis of Helicobacter pylori infection. Helicobacter, 16 Suppl 1, 19-25. 10. Hatakeyama, M. (2014). Helicobacter pylori CagA and gastric cancer: a paradigm for hit-and-run carcinogenesis. Cell Host & Microbe, 15(3), 306-316. 11. Savoldi, A., Carrara, E., Graham, D. Y., et al. (2018). Prevalence of antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis in World Health Organization regions. Gastroenterology, 155(5), 1372-1382.e17. 12. Malfertheiner, P., Bazzoli, F., Delchier, J. C., et al. (2012). Helicobacter pylori eradication with a new formulation of bismuth quadruple therapy: a randomized trial. Alimentary Pharmacology & Therapeutics, 36(4), 350-360. 13. Graham, D. Y., Lee, Y. C., & Wu, M. S. (2014). Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clinical Gastroenterology and Hepatology, 12(2), 177-186.e3. 14. Megraud, F., Coenen, S., Versporten, A., et al. (2021). Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut, 70(5), 1815-1824. 15. Fallone, C. A., et al. (2022). New and emerging therapies for Helicobacter pylori infection: from bench to bedside. Alimentary Pharmacology & Therapeutics, 56(7), 1026-1040. 16. Yamaoka, Y. (2010). Mechanisms of disease: Helicobacter pylori virulence factors. Nature Reviews Gastroenterology & Hepatology, 7(11), 629-641. 17. Kusters, J. G., van Vliet, A. H., & Kuipers, E. J. (2006). Pathogenesis of Helicobacter pylori infection. Clinical Microbiology Reviews, 19(3), 449-490. 18. Jones, N. L., Koletzko, S., Goodman, K., et al. (2017). Joint ESPGHAN/NASPGHAN guidelines for the management of Helicobacter pylori in children and adolescents. Journal of Pediatric Gastroenterology and Nutrition, 64(6), 991-1003. 19. Dore, M. P., Sepulveda, A. R., Realdi, G., et al. (2020). Probiotics as adjuvants in Helicobacter pylori eradication therapy: a systematic review and meta-analysis. European Journal of Gastroenterology & Hepatology, 32(3), 305-312. 20. Gisbert, J. P., & Calvet, X. (2011). Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. Alimentary Pharmacology & Therapeutics, 33(9), 983-994. 21. World Health Organization (2014). IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Volume 100B. Biological Agents. Lyon: IARC. 22. Graham, D. Y. (2015). Helicobacter pylori update: gastric cancer, reliable therapy, and possible benefits. Gastroenterology, 148(4), 719-731.